Evidence map›Paper›PMID 40432489›Full record

ArticleChemMedChem2025

Factors Influencing the Binding of HIV-1 Protease Inhibitors: Insights from Machine Learning Models.

Yaffa Shalit, Inbal Tuvi-Arad

Abstract read
In one paragraph

Article in ChemMedChem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yaffa ShalitDepartment of Natural Sciences, The Open University of Israel, Raanana, 4353701, Israel.
Inbal Tuvi-AradDepartment of Natural Sciences, The Open University of Israel, Raanana, 4353701, Israel.ORCID https://orcid.org/0000-0003-0418-9915

Funding

Open University Research Fund 515013Wellcome Trust 102558
6 · The paper itself

Abstract

HIV-1 protease (PR) inhibitors are crucial for antiviral therapies targeting acquired immunodeficiency syndrome. Hundreds of PR complexes with various ligands have been resolved and deposited in the Protein Data Bank. However, binding affinity measurements for these ligands are not always available. This gap hinders a comprehensive understanding of inhibitor efficacy. To address this challenge, machine learning models are constructed and validated based on the crystallographic coordinates of 291 PR-inhibitor complexes, leveraging over 2500 molecular descriptors. The models achieved accuracy scores exceeding 0.85, and applied to predict the binding affinity of 274 additional complexes for which inhibition constants are not experimentally measured. The analysis is focused on three models, each with 8-9 features, and based on KBest with random forest, recursive feature elimination with random forest, and sequential feature selection with support vector machine. The findings revealed key predictive features, including properties of PR inhibitors like charge distribution, hydrogen-bonding capability, and 3D topology, as well as intrinsic properties of PR, such as active site symmetry and flap mutations. The study highlights the contribution of a comprehensive analysis of accumulated experimental data to enhance the structural understanding of this important molecular system.

Indexed as

HIV-1HIV ProteaseHIV Protease InhibitorsMachine LearningBinding SitesHumansModels, MolecularMolecular StructureHIV ProteaseHIV Protease Inhibitorsp16 protease, Human immunodeficiency virus 1crystal structurehuman immunodeficiency virusligand bindingmachine learningsymmetry

Identifiers

PMID40432489
PMCPMC12321272

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.